17‰ρ@VŠƒtƒVƒ“ƒ|ƒWƒEƒ€

tŽΎŠ³‚ΖƒQƒmƒ~ƒNƒXEƒvƒƒeƒIƒ~ƒNƒXŒ€‹†

•½¬14”N7ŒŽ27“ϊ

ŠJ‰ο‚ΜŽ« VŠƒ‘εŠw–Ό—_‹³Žφ rμ³Ί

‘ζ1•”@
ΐ’· ‰Ίπ•Ά•
‰Ν“ΰ@—T

Ž‰–bΧ–E‚ƐΆŠˆKŠ΅•a‚Μ•ͺŽq‹@\ “Œ‹ž‘εŠw‘εŠw‰@ˆγŠwŒnŒ€‹†‰Θ@“œ”A•a‘γŽΣ“ΰ‰Θ –ε˜e@F

DNA array‚π—p‚’‚½ŽΐŒ±t‰Š‚Μ‰πΝ‚ΖŽ‘—Γ VŠƒ‘εŠw‘εŠw‰@ˆγŽ•Šw‘‡Œ€‹†‰ΘtδPŒ΄•a“ΰ‰Θ ‹ΰŽq‰ΐŒ«Aβ’άŽΐA¬“cˆκ‰qA‰Ίπ•Ά•

‘ζ2•”

ΐ’· ’ΗŽθ@›Ω
@@ •y“cŠμ•F

Importance of mitochondorial porteins for apoptosis or multidrug resistance of transitional cell cancer cell VŠƒ‘εŠw‘εŠw‰@ˆγŽ•Šw‘‡Œ€‹†‰ΘtE”ε”AŠν•a‘ΤŠw V. Bilim, Noboru Hara, Takashi Kasahara, Kota Takahashi, Yoshihiko Tomita

”A’`”’‚ΜƒvƒƒeƒIƒ~ƒNƒX VŠƒ‘εŠw‘εŠw‰@ˆγŽ•Šw‘‡Œ€‹†‰ΘtδPŒ΄•a“ΰ‰Θ β’άŽΐA¬“cˆκ‰qA‰Ίπ•Ά•

_ŒoŽΎŠ³‚ΜƒvƒƒeƒIƒ~ƒNƒX ŒF–{‘εŠwˆγŠw•”Žξα‡ˆγŠw r–ؗߍ]

‘ζ3•”
ΐ’· ŽR–{@Ši
@@ ‘ε‹v•Ϋ‘ˆκ˜Y

ƒqƒgtŽ…‹…‘Μƒ^ƒ“ƒpƒNŽΏƒf[ƒ^ƒx[ƒX‚̍\’z‚Ζ‚»‚Μ—˜—p VŠƒ‘εŠwtŒ€‹†Ž{έ\‘’•a—Šw ‹g“c–LAγ‰ΖˆκAŽR–{Ši
NECŠξ‘bŒ€‹†ŠƒvƒƒeƒIƒ~ƒNƒXƒZƒ“ƒ^[ ‹{θŒ«ŽiAŽŸ“cα©

ƒvƒƒeƒIƒ~ƒNƒXŒ€‹†‚̍ŋ߂̐i•ΰ “Œ‹ž“s—§‘εŠw‘εŠw‰@—ŠwŒ€‹†‰Θ ˆι•”r–Ύ

•Β‰ο‚ΜŽ« ΄…•s“ρ—Y